{"product_id":"proteogenix-anti-cov-rbd-a12-antibody","title":"Anti-CoV-RBD (A12) antibody","description":"\u003ch2\u003eGeneral information on Anti-CoV-RBD (A12) antibody\u003c\/h2\u003e \u003cp\u003eThe receptor-binding domain (RBD) of the spike protein of SARS-CoV-2 is the most relevant target used for the design of new treatments for COVID-19. The development of antibodies able to target this specific region can be carried out either in vivo, which is a time-demanding process or in vitro, which capitalizes on the flexibility of display technologies such as phage display.\u003c\/p\u003e \u003cp\u003eThe anti-CoV-RBD (A12) antibody was developed by phage display screening of a vast COVID-19 antibody library (LiAb-SFCOVID-19™) against the RBD of SARS-CoV-2. Given that antibody production by phage display does not require animal immunization nor the use of immunogenic antigens, only the small RBD protein was used to isolate specific RBD-binders from the LiAb-SFCOVID-19™ library. Moreover, since this library comprises the immune repertoire of COVID-19 patients, it has the greatest abundance of biologically relevant antibodies with potent neutralizing activity.\u003c\/p\u003e \u003cp\u003eThis specific antibody is thus a fully human immunoglobulin in IgG format. Its affinity towards recombinantly expressed RBD was tested and validated through enzyme-linked immunosorbent assay (ELISA). Additionally, the neutralizing activity was tested using the SARS-CoV-2 Surrogate Virus Neutralization Test (sVNT) assay which was designed to quickly assess the neutralizing potential of new antibodies without the need of using native viral particles.\u003c\/p\u003e \u003cp\u003eLastly, the IgG antibody was expressed in XtenCHO™, a highly productive transient mammalian system, and shown to be very stable and consistently generate high production yields.\u003c\/p\u003e\u003cp\u003eProteoGenix catalogue number PTXCOV-A521A. For research use only.\u003c\/p\u003e\u003cp\u003eTarget: RBD domain- SARS-CoV2 Spike protein; Clonality: Monoclonal Antibody; Expression system: Mammalian; Purity: 85%; Molecular weight: 150kDa; Buffer: PBS, pH7,5.\u003c\/p\u003e\u003cp\u003eAvailable configurations: 50ug, 100ug, 1mg.\u003c\/p\u003e\u003cp\u003e\u003ca href=\"https:\/\/www.proteogenix.science\/wp-content\/uploads\/documents\/Datasheets\/PTXCOV-A521A.pdf\"\u003eDownload the manufacturer datasheet\u003c\/a\u003e\u003c\/p\u003e","brand":"ProteoGenix","offers":[{"title":"50ug","offer_id":57357546651988,"sku":"ABM133512-1","price":220.0,"currency_code":"USD","in_stock":true},{"title":"100ug","offer_id":57357546684756,"sku":"ABM133512-2","price":297.0,"currency_code":"USD","in_stock":true},{"title":"1mg","offer_id":57357546717524,"sku":"ABM133512-3","price":950.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/1040\/1782\/2036\/files\/sds-validation-anti-cov-rbd-a12-antibody_121c43d5-7ee1-4378-824f-0de21d4df70c.jpg?v=1790890693","url":"https:\/\/www.abmium.com\/fr\/products\/proteogenix-anti-cov-rbd-a12-antibody","provider":"ABMIUM","version":"1.0","type":"link"}